Innovations in epilepsy management - An overview

Journal of Pharmacy and Pharmaceutical Sciences

Volumn 16, Issue 4, 2013, Pages 564-576

  Shaju, Minumaria ^a   Abraham, Suja ^a  

^a AMRITA INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

[No Author keywords available]

Indexed keywords

AMITRIPTYLINE; CARBAMAZEPINE; CLOBAZAM; DIAZEPAM; ESLICARBAZEPINE ACETATE; ETIRACETAM; FELBAMATE; GABAPENTIN; HARKOSERIDE; LAMOTRIGINE; LORAZEPAM; NIMODIPINE; NORCLOBAZAM; NORTRIPTYLINE; OXCARBAZEPINE; PAROXETINE; PERAMPANEL; PHENOBARBITAL; PHENYTOIN; PRIMIDONE; RETIGABINE; RUFINAMIDE; STIRIPENTOL; TIAGABINE; TOPIRAMATE; UNINDEXED DRUG; VALPROIC ACID; VIGABATRIN; ZIDOVUDINE; ZONISAMIDE;

ABSENCE; ADD ON THERAPY; ADJUVANT THERAPY; AGGRESSIVENESS; ANHIDROSIS; ANOREXIA; APLASTIC ANEMIA; ASTHENIA; ATAXIA; BEHAVIOR CHANGE; BIPOLAR DISORDER; BLOOD DYSCRASIA; BLURRED VISION; COGNITIVE DEFECT; CONCENTRATION LOSS; CONFUSION; COORDINATION DISORDER; DEPRESSION; DIPLOPIA; DIZZINESS; DOSE RESPONSE; DROWSINESS; DRUG ANTAGONISM; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG FORMULATION; DRUG MECHANISM; DRUG POTENTIATION; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSTONIA; EPILEPSY; EPILEPTIC STATE; EXCITABILITY; FALLING; FATIGUE; FEBRILE CONVULSION; FOCAL EPILEPSY; GAIT DISORDER; GASTROINTESTINAL SYMPTOM; GENERALIZED ANXIETY DISORDER; GENERALIZED EPILEPSY; HEADACHE; HUMAN; HYPONATREMIA; HYPOTHERMIA; INFANTILE SPASM; INSOMNIA; IRRITABILITY; LANGUAGE DISABILITY; LENNOX GASTAUT SYNDROME; LEUKOPENIA; LIVER FAILURE; METABOLIC ACIDOSIS; MYOCLONUS EPILEPSY; NAUSEA; NEPHROLITHIASIS; OPEN ANGLE GLAUCOMA; OTITIS MEDIA; PARESTHESIA; PERIPHERAL EDEMA; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHOTOSENSITIVITY; RASH; REVIEW; SEDATION; SIDE EFFECT; SOMNOLENCE; STEVENS JOHNSON SYNDROME; STUPOR; SUICIDAL BEHAVIOR; TIC; TONIC CLONIC SEIZURE; TOXIC EPIDERMAL NECROLYSIS; TREMOR; UNSPECIFIED SIDE EFFECT; URINE RETENTION; VISUAL FIELD DEFECT; VISUAL IMPAIRMENT; WEAKNESS; WEIGHT GAIN; WEIGHT REDUCTION;

ANIMALS; ANTICONVULSANTS; DRUG INTERACTIONS; EPILEPSY; HUMANS;

EID: 84884753607     PISSN: None     EISSN: 14821826     Source Type: Journal    
DOI: 10.18433/j32k5b     Document Type: Review

References (88)

1. Hwang H, Kim KJ. New antiepileptic drugs in Pediatric Epilepsy. Brain & Development, 2008;30:549-555
2. Kwan P, Brodie M. Early identification of refractory epilepsy. New Engl J Med, 2000:342:314-319
3. Ravat SH, Gupta R. antiepileptic drugs in Pediatric epilepsy. J Pediatr Neurosci, 2008;3:7-15
4. Perucca E. the new generation of antiepileptic drugs: Advantages and disadvantages. Br J clin Pharmacol, 1996;42:531-543
5. Gatti G, Bonomi I et al. the new antiepileptic drugs: Pharmacological and clinical aspects. Curr Pharm Des, 2000;6(8):839-860
6. Goldenberg MM. Overview of drugs used for epilepsy and seizures-Etiology, diagnosis and treatment. PT, 2010;35(7):392-415
7. Theodore WH. Rational use of antiepileptic drug levels. Pharmacol Ther, 1992;54:297-305
8. Eadie MJ. The role of therapeutic drug monitoring in improving the cost effectiveness of anticonvulsant therapy. Clin Pharmacokinet, 1995;29:29-35
9. Beghi E, Perucca E. The management of epilepsy in the 1990s: Acquisitions, uncertainities and perspectives for future research. Drugs, 1995;49:680-694
10. Perucca E, Dulac O et al. Harnessing the clinical potential of antiepileptic drug therapy: Dosage optimization. CNS Drugs, 2001;15:609-621
11. Rocha GP, Batista BH. Use of psychoactive and antiepileptic drugs: Guidelines for pediatricians. J Pediatr(Rio J), 2004;80(2):45-55
12. French JA, Kanner AM et al. Efficacy and Tolerability of the new antiepileptic drugs I: Treatment of new onset epilepsy. Neurology, 2004;62:1252-1260
13. Perucca E. The spectrum of the new antiepileptic drugs. Acta Neurol Belgica, 1999;99:231-238
14. Perucca E, Gram L et al. Antiepileptic drugs as a cause of worsening seizures. Epilepsia, 1998;39:5-17
15. Chiron C, Dulac O. The pharmacologic treatment of Dravet syndrome. Epilepsia, 2011;52(2):72-75
16. Troninar MK, Wojtal K et al. A novel antiepileptic drug. Pharmacological Reports, 2005;57:154-160
17. Brodie MJ. Do we need any more antiepileptic drugs? Epilepsy, Res 2001;45:3-6
18. Levy RH, Loiseau P et al. Stiripentol kinetics in epilepsy: nonlinearity and interactions. Clin Pharmacol Ther, 1984;36:661-669
19. Chiron C, Marchand MC et al. Stiripentol in severe myoclonic epilepsy in infancy: a randomized placebo controlled syndrome dedicated trial. STILCO study group. Lancet, 2000;356:1638-1642
20. Perez J, Chiron C et al. Stiripentol: efficacy and tolerability in children with epilepsy. Epilepsia, 1999;40:1618-1626
21. Ben ME, Biton V et al. Efficacy and safety of oral lacosamide as adjunctive therapy in adults with partial onset seizures. Epilepsia, 2007;48:1308-1317
22. Pressman P. Optimal use of the newest antiepileptic drugs and genetics. The Neurology Report, 2013;5(3):24-34
23. Perucca E, Cloyd J et al. Rufinamide: clinical pharmacokinetics and concentration response relationships in patients with epilepsy. Epilepsia, 2008;49:1123-1141
24. Bialer M, Silva P. Pharmacokinetics and drug interactions of eslicarbazepine acetate. Epilepsia, 2012;53:935-946
25. Ben ME, Gabbaib AA et al. Eslicarbazepine acetate as adjunctive therapy in adult patients with partial epilepsy. Epilepsy Res, 2010;89:278-285
26. French JA, Abou-Khalil BW et al. Randomized double blind, placebo controlled trial of ezogabine (retigabine) in partial epilepsy. Neurology, 2011;76(18):1555-1563
27. Tolman JA, Faulkner MA. Vigabatrin: a comprehensive review of drug properties including clinical updates following recent FDA approval. Expert Opinion on pharmacotherapy, 2009;10(18):3077-3089
28. Ng YT, Conry JA et al. Randomized phase III study results of clobazam in Lennox Gastaut syndrome. Neurology, 2011;77:1473-1481
29. French JA, Kanner AM. Efficacy and tolerability of the new antiepileptic drugs II: Treatment of refractory epilepsy. Neurology, 2004;62:1261-1273
30. Schmidt D. Efficacy of new antiepileptic drugs. Epilepsy Currents, 2011;11(1):9-11
31. Cereghino JJ, Biton V et al. Levetiracetam for partial seizures: Results of a double blind, randomized clinical trial. Neurology, 2000;55(2):236-242
32. Hiba A, Richard B et al. Comparative effectiveness of 10 antiepileptic drugs in older adults with epilepsy. Arch Neurol, 2010;67(4):408-415
33. Guberman A, Bruni J et al. Long term open multicentre, add-on trial of vigabatrin in adult resistant partial epilepsy. Seizure, 2000;9(2):112-118
34. Grosso S, Franzoni E et al. Efficacy and safety of topiramate in refractory epilepsy of childhood: long term follow up study. J Child Neurol, 2005;20(11):893-897
35. Coppola G, Caliendo G et al. Topiramate as add-on drug in children, adolescents and young adults with Lennox Gastaut syndrome: An Italian multicentric study. Epilepsy Res, 2002;51(1-2):147-153
36. Privitera, Brodie MJ et al. Topiramate, carbamazepine and valproate monotherapy: double blind comparison in newly diagnosed epilepsy. Acta Neurol Scand, 2003;107:165-175
37. Baulac M, Brodie Mj et al. Efficacy and tolerability of zonisamide versus controlled release carbamazepine for newly diagnosed partial epilepsy: A phase III randomized, double blind, noninferiority trial. Lancet Neurol, 2012;11(7):579-588
38. Kothare S, Valencia I et al. Efficacy and tolerability of zonisamide in juvenile myoclonic epilepsy. Epileptic Disord, 2004;6:267-270
39. Guerreiro MM, Vigonius U et al. A double blind controlled clinical trial of oxcarbazepine versus phenytoin in children and adolescents with epilepsy. Epilepsy Res, 1997;27(3):205-213
40. David M, Labiner. Old versus new antiepileptic drugs: time for a paradigm shift? Advanced studies in nursing, 2005;3(4):105-112
41. Chadwick DW, Anhu H et al. A double blind trial of gabapentin monotherapy for newly diagnosed partial seizures. Neurology, 1998;51:1282-1288
42. Michael MJ, Martha MJ et al. Safety and tolerability of Gabapentin as adjunctive therapy in a large, multicenter study. Epilepsia, 1999;40(7):965-972
43. Steiner TJ, Dellaportas Cl et al. Lamotrigine monotherapy in newly diagnosed untreated epilepsy: A double blind comparison with phenytoin. Epilepsia, 1999;40:601-607
44. Mockenhaupt M, Messenheimer J et al. Risk of Stevens-Johnson syndrome and toxic epidermal necrolysis in new users of antiepileptics. Neurology, 2005;64:1134-1138
45. Morrella JM, Isojarvi J et al. Higher androgens and weight gain with valproate compared with lamotrigine for epilepsy. Epilepsy Res, 2003;54(2-3):189-199
46. Mula M. Topiramate and cognitive impairment: Evidence and clinical implications. Therapeutic Advances in Drug Safety, 2012;3:279-289
47. Bumb A, Diederich N et al. Adding topiramate to valproate therapy may cause reversible hepatic failure. Epileptic Disord, 2003;5:157-159
48. Shorvon D. Safety of Topiramate: Adverse events and relationships to dosing. Epilepsia, 1996;37:18-22
49. Guerreiro MM, Vigonius U et al. A double blind controlled clinical trial of oxcarbazepine versus phenytoin in children and adolescents with epilepsy. Epilepsy Res, 1997;27(3):205-213
50. Dam M, Ekberg R et al. A double blind study comparing oxcarbazepine and carbamazepine in patients with newly diagnosed, previously untreated epilepsy. Epilepsy Res, 1989;3:70-76
51. Zamponi N, Cardinall C et al. Open comparative long term study of vigabatrin versus carbamazepine in newly diagnosed partial seizures in children. Arch Neurol, 1999;56:605-607
52. Kalviainen R, Aikia M et al. Vigabatrin versus carbamazepine monotherapy in patients with newly diagnosed epilepsy: A randomized, controlled study. Arch Neurol, 1995;52(10):989-996
53. Patsalos PN, Perucca E et al. Clinically important drug interactions in epilepsy: General features and interactions between antiepileptic drugs. Lancet Neurol, 2003;2(6):347-356
54. Hachad, Houda et al. New antiepileptic drugs: Review on drug interactions. Therapeutic Drug Monitoring, 2002;24(1):91-103
55. Perucca E. Clinically relevant drug interactions with antiepileptic drugs. Br J Clin Pharmacol, 2006;61(3):246-255
56. Johannessen C, Patsalos PN. Drug interactions involving new second and third generation antiepileptic drugs. Expert Rev. Neurother, 2010;10(1):119-140
57. Adkins JC, Noble S. Tiagabine: A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in the management of epilepsy. Drugs, 1998;55(3):437-460
58. Bialer M, Johannessen SI et al. Progress report on new antiepileptic drugs: a summary of the Eighth EILAT Conference(EILAT VIII). Epilepsy Res, 2007;73:1-52
59. Deeks ED, Scott LJ. Rufinamide. CNS Drugs, 2006;20:751-760
60. Kerr BM, Martinez-Lage JM et al. Carbamazepine dose requirements during stiripentol therapy: influence of cytochrome P450 inhibition by stiripentol. Epilepsia, 1991;32:267-274
61. Rey E, Tran A et al. Stiripentol potentiates clobazam in childhood epilepsy: a pharmacological study. Epilepsia, 1999;40(7):112-113
62. Bialer M, Johannessen SI et al. Progress report on new antiepileptic drugs: a summary of the Ninth EILAT Conference(EILAT IX). Epilepsy Res, 2009;83:1-43
63. Elger C, Bialer M et al. Eslicarbazepine acetate: a doubleblind, add-on, placebo controlled exploratory trial in adult patients with partial onset seizures. Epilepsia, 2007;48:497-504
64. Ferron GM, Patat A et al. Lack of pharmacokinetic interaction between retigabine and phenobarbitone at steady state in healthy subjects. Br J Clin Pharmacol, 2003;56:39-45
65. Hermann R, Knebel NG et al. Pharmacokinetic interaction between retigabine and lamotrigine in healthy subjects. Eur J Clin Pharmacol, 2003;58:795-802
66. Vecht CJ, Wagner GL et al. Interactions between antiepileptic and chemotherapeutic drugs. Lancet Neurol, 2003;2:404-409
67. De Turck BJ, Diltoer MW et al. Lowering of plasma valproic acid concentrations during concomitant therapy with meropenem and amikacin. J Antimicrob Chemother, 1998;42:563-564
68. Perucca E. the clinical pharmacology and therapeutic use of the new antiepileptic drugs. Fund Clin Pharmacol, 2001;15:405-417
69. Harder S, Thurmann P. Clinically drug interactions with anticoagulants: An update. Clin Pharmacokin, 1996;30:416-444
70. Hassan Y, Awaisu A et al. The complexity of achieving anticoagulation control in the face of warfarin-phenytoin interaction: An Asian case report. Pharm World Sci, 2005;27:16-9
71. Stephen LJ. Drug treatment of epilepsy in elderly people: Focus on valproic acid. Drugs Aging, 2003;20:141-152
72. Schulze B, Andreas. Brivaracetam for the treatment of epilepsy. Expert Opinion on Pharmacotherapy, 2011;12(12):1959-1966
73. Sargentini-Maier ML, Espie P et al. Pharmacokinetics and metabolism of 14Cbrivaracetam, a novel SV2A ligand in healthy subjects. Drug Metab. Dispos, 2008;36:36-45
74. Otoul C, von Rosenstiel P et al. Evaluation of the pharmacokinetic interaction of brivaracetam on other antiepileptic drugs in adults with partial onset seizures. Epilepsia, 2007;48:334-340
75. Bennet B, Matagne A et al. Seletracetam(UCB 44212). Neurotherapeutics, 2007;4:117-122
76. Luszczki JJ. Third generation antiepileptic drugs: mechanisms of action, pharmacokinetics and interactions. Pharmacological Reports, 2009;61:197-216
77. Halford JJ, Ben-Menachem E et al. A randomized, double-blind, placebo controlled study of the efficacy, safety and tolerability of adjunctive carisbamate treatment in patients with partial onset seizures. Epilepsia, 2011;52(4):816-825
78. Novak GP, Kelly M et al. Carisbamate(RWJ-333369). Neurotherapeutics, 2007;4:106-109
79. Kulig K, Malawska B. Carisbamate, a new carbamate for the treatment of epilepsy. IDrugs, 2007;10(10):720-727
80. Monaghan EP, McAuley JW et al. Ganaxolone: A novel positive allosteric modulator of the GABA receptor complex for the treatment of epilepsy. Expert Opin Investig Drugs, 1999;8:1663-1671
81. Pieribone VA, Tsai J et al. Clinical evaluation of Ganaxolone in pediatric and adolescent patients with refractory epilepsy. Epilepsia, 2007;48:1870-1874
82. Nohria V, Giller E. Ganaxolone. Neurotherapeutics, 2007;4:102-105
83. Kerrigan JF, Shields DW et al. Ganaxolone for treating intractable infantile spasms: A multicenter, open-label, add-on trial. Epilepsy Res, 2000;42(2):133-139
84. Langan YM, Lucas R et al. Telampanel, A new antiepileptic drug: Single and multiple dose pharmacokinetics and initial 1-week experience in patients with chronic intractable epilepsy. Epilepsia, 2003;44:46-53
85. Chappell AS, Sander JW et al. A crossover, add-on trial of talampanel in patients with refractory partial seizures. Neurology, 2002;58(11):1680-1682
86. Mazarati AM, Sofia RD et al. Anticonvulsant and antiepileptogenic effects of Fluorofelbamate in experimental status epilepticus. Seizure, 2002;11(7):423-430
87. Baulac M, Klement S. Efficacy and safety of Losigamone in partial seizures: A randomized double blind study. Epilepsy Res, 2003;55:177-189
88. Kimber-Trojnar Z, Borowicz KK et al. Perspectives of losigamone in epilepsy treatment. Pol J Pharmacol, 2003;55(5):675-682